Suppr超能文献

CD133 是一类独特的原始人脐带血来源的 CD34 阴性造血干细胞的阳性标志物。

CD133 is a positive marker for a distinct class of primitive human cord blood-derived CD34-negative hematopoietic stem cells.

机构信息

1] Department of Stem Cell Biology and Regenerative Medicine, Graduate School of Medical Science, Kansai Medical University, Hirakata, Osaka, Japan [2] Department of Pediatrics, Kansai Medical University, Hirakata, Osaka, Japan.

Department of Stem Cell Biology and Regenerative Medicine, Graduate School of Medical Science, Kansai Medical University, Hirakata, Osaka, Japan.

出版信息

Leukemia. 2014 Jun;28(6):1308-15. doi: 10.1038/leu.2013.326. Epub 2013 Nov 5.

Abstract

The identification of human CD34-negative (CD34(-)) hematopoietic stem cells (HSCs) provides a new concept for the hierarchy in the human HSC compartment. Previous studies demonstrated that CD34(-) severe combined immunodeficiency (SCID)-repopulating cells (SRCs) are a distinct class of primitive HSCs in comparison to the well-characterized CD34(+)CD38(-) SRCs. However, the purification level of rare CD34(-) SRCs in 18 lineage marker-negative (Lin(-)) CD34(-) cells (1/1000) is still very low compared with that of CD34(+)CD38(-) SRCs (1/40). As in the mouse, it will be necessary to identify useful positive markers for a high degree of purification of rare human CD34(-) SRCs. Using 18Lin(-)CD34(-) cells, we analyzed the expression of candidate positive markers by flow cytometric analysis. We finally identified CD133 as a reliable positive marker of human CB-derived CD34(-) SRCs and succeeded in highly purifying primitive human CD34(-) HSCs. The limiting dilution analysis demonstrated that the incidence of CD34(-) SRCs in 18Lin(-)CD34(-)CD133(+) cells was 1/142, which is the highest level of purification of these unique CD34(-) HSCs to date. Furthermore, CD133 expression clearly segregated the SRC activities of 18Lin(-)CD34(-) cells, as well as 18Lin(-)CD34(+) cells, in their positive fractions, indicating its functional significance as a common cell surface maker to isolate effectively both CD34(+) and CD34(-) SRCs.

摘要

人类 CD34 阴性(CD34(-))造血干细胞(HSCs)的鉴定为人类 HSC 区室中的层次结构提供了新概念。先前的研究表明,与特征明确的 CD34(+)CD38(-)SRC 相比,CD34(-)严重联合免疫缺陷(SCID)-重建造血细胞(SRC)是一类独特的原始 HSCs。然而,与 CD34(+)CD38(-)SRC 相比,18 系标记阴性(Lin(-))CD34(-)细胞(1/1000)中罕见的 CD34(-)SRC 的纯化水平仍然非常低(1/40)。与小鼠一样,有必要鉴定有用的阳性标记物,以实现罕见的人类 CD34(-)SRC 的高度纯化。我们使用 18Lin(-)CD34(-)细胞通过流式细胞术分析来分析候选阳性标记物的表达。我们最终确定 CD133 为人类 CB 衍生的 CD34(-)SRC 的可靠阳性标记物,并成功地高度纯化了原始的人类 CD34(-)HSCs。有限稀释分析表明,18Lin(-)CD34(-)CD133(+)细胞中 CD34(-)SRC 的发生率为 1/142,这是迄今为止这些独特的 CD34(-)HSCs 的最高纯化水平。此外,CD133 表达清楚地将 18Lin(-)CD34(-)细胞以及 18Lin(-)CD34(+)细胞的 SRC 活性分离在其阳性部分中,表明其作为一种有效的共同细胞表面标记物来分离 CD34(+)和 CD34(-)SRC 的功能意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7192/4051213/36100fa14681/leu2013326f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验